Evaluating vibegron for the treatment of overactive bladder
- 29 September 2020
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 22 (1) , 9-17
Abstract
Vibegron is a very selective new β3-adrenergic receptor agonist introduced recently to clinical practice for OAB patients, which offers an alternative option for to antimuscarinic drugs.This review...Keywords
This publication has 36 references indexed in Scilit:
- Comparative Analysis of the Effects of Antimuscarinic Agents on Bladder Functions in Both Nonhuman Primates and RodentsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Urothelial beta‐3 adrenergic receptors in the rat bladderNeurourology and Urodynamics, 2010
- β−Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladderCell and tissue research, 2010
- The β3‐adrenoceptor mediates the inhibitory effects of β‐adrenoceptor agonists via the urothelium in pig bladder domeNeurourology and Urodynamics, 2010
- Aging and the underactive detrusor: A failure of activity or activation?Neurourology and Urodynamics, 2009
- The β3-adrenoceptor as a therapeutic target: Current perspectivesPharmacological Research, 2009
- Dual Use of Bladder Anticholinergics and Cholinesterase Inhibitors: Long‐Term Functional and Cognitive OutcomesJournal of the American Geriatrics Society, 2008
- Neuronally Released Acetylcholine Acts on the M2 Muscarinic Receptor to Oppose the Relaxant Effect of Isoproterenol on Cholinergic Contractions in Mouse Urinary BladderThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Increased Relaxant Action of Forskolin and Isoproterenol against Muscarinic Agonist-Induced Contractions in Smooth Muscle from M2 Receptor Knockout MiceThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Localization of the β(beta)3‐adrenoceptor in the human gastrointestinal tract: an immunohistochemical studyAlimentary Pharmacology & Therapeutics, 1998